Treatment group | Â | Days post-treatmenta
|
---|
Day 0 | Day 28–30 | Day 54-60 |
---|
Sarolanerb
| # Dogs | 29 | 29 | 28 |
Mean CADESI - 4 Scored
| 35.41 | 17.62 | 11.54 |
SD | 22.79 | 16.21 | 9.78 |
Range | 4–94 | 0–71 | 0–39 |
Reduction (%)e
| Â | 50.24 | 67.43 |
Spinosadc
| # Dogs | 26 | 26 | 25 |
Mean CADESI - 4 Scored
| 32.65 | 16.58 | 12.28 |
SD | 20.50 | 13.43 | 9.60 |
Range | 1–91 | 1–58 | 3–43 |
Reduction (%)e
| Â | 49.23 | 62.39 |
-
Abbreviation:Â SD standard deviation
- No significant differences between the two groups were observed, for any day, based on the repeated measures analysis (PÂ =Â 0.8588)
-
aIn both groups, dogs were treated on day 0 and once between days 56–60
-
bDogs were orally administered Sarolaner chewables (Simparica® Zoetis) according to label directions
-
cDogs were orally administered Spinosad flavored tablets (Comfortis® Elanco) according to label directions
-
dArithmetic mean Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4 scores [34]
-
e{(Day 0 arithmetic mean CADESI-4 score – day x arithmetic mean CADESI-4 score) / day 0 arithmetic mean CADESI-4 score)} × 100